메뉴 건너뛰기




Volumn 67, Issue 6, 2011, Pages 613-623

Risk of high-grade bleeding in patients with cancer treated with bevacizumab: A meta-analysis of randomized controlled trials

Author keywords

Bevacizumab; Bleeding; Chemotherapy; Meta analysis

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO;

EID: 79959710296     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-010-0988-x     Document Type: Article
Times cited : (83)

References (41)
  • 1
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 2
    • 0036984640 scopus 로고    scopus 로고
    • Role of angiogenesis in tumor growth and metastasis
    • Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
    • (2002) Semin Oncol , vol.29 , pp. 15-18
    • Folkman, J.1
  • 3
    • 13444278498 scopus 로고    scopus 로고
    • Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    • Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
    • (2005) Cancer Res , vol.65 , pp. 671-680
    • Gerber, H.P.1    Ferrara, N.2
  • 4
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • DOI 10.1200/JCO.2006.09.6305
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, SchwartzMA, Benson AB 3rd (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544 (Pubitemid 46733080)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.12 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson III, A.B.8
  • 7
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3    Meropol, N.J.4    Novotny, W.F.5    Lieberman, G.6    Griffing, S.7    Bergsland, E.8
  • 9
  • 12
    • 54249120945 scopus 로고    scopus 로고
    • Randomized, double-blind,placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
    • Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG (2008) Randomized, double-blind,placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc Am Soc Clin Oncol 26:LBA1011
    • (2008) Proc Am Soc Clin Oncol , vol.26
    • Miles, D.1    Chan, A.2    Romieu, G.3    Dirix, L.Y.4    Cortes, J.5    Pivot, X.6    Tomczak, P.7    Taran, T.8    Harbeck, N.9    Steger, G.G.10
  • 16
    • 84885707194 scopus 로고    scopus 로고
    • Available at; Accessed 27 Oct 2008
    • Genentech. Bevacizumab prescribing information. Available at; http://www.Gene.com/gene/products/information/oncology/avastin/. Accessed 27 Oct 2008
    • Bevacizumab Prescribing Information
  • 19
    • 36048982143 scopus 로고    scopus 로고
    • Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    • Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:474-4750
    • (2007) J Clin Oncol , vol.25 , pp. 474-4750
    • Herbst, R.S.1    O'Neill, V.J.2    Fehrenbacher, L.3    Belani, C.P.4    Bonomi, P.D.5    Hart, L.6    Melnyk, O.7    Ramies, D.8    Lin, M.9    Sandler, A.10
  • 20
    • 54249108586 scopus 로고    scopus 로고
    • Initial safety report of NSABP C-08, a randomized phase III study of odify ed 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer
    • Abstr 4006
    • Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Wolmark N (2008) Initial safety report of NSABP C-08, a randomized phase III study of odify ed 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. Proc Am Soc Clin Oncol 26 [15 Suppl]: Abstr 4006
    • (2008) Proc Am Soc Clin Oncol , vol.26 , Issue.15 SUPPL.
    • Allegra, C.J.1    Yothers, G.2    O'Connell, M.J.3    Sharif, S.4    Wolmark, N.5
  • 22
    • 35548941394 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB)
    • Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). Proc Am Soc Clin Oncol 25:4508
    • (2007) Proc Am Soc Clin Oncol , vol.25 , pp. 4508
    • Kindler, H.L.1    Niedzwiecki, D.2    Hollis, D.3    Oraefo, E.4    Schrag, D.5    Hurwitz, H.6    McLeod, H.L.7    Mulcahy, M.F.8    Schilsky, R.L.9    Goldberg, R.M.10
  • 23
    • 40749158416 scopus 로고    scopus 로고
    • Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
    • Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, Chen H, Stadler WM, Vokes E (2007) Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 25:7526
    • (2007) J Clin Oncol , vol.25 , pp. 7526
    • Karrison, T.1    Kindler, H.L.2    Gandara, D.R.3    Lu, C.4    Guterz, T.L.5    Nichols, K.6    Chen, H.7    Stadler, W.M.8    Vokes, E.9
  • 25
    • 77958495206 scopus 로고    scopus 로고
    • AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
    • Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA (2010) AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28: LBA4007
    • (2010) J Clin Oncol , vol.28
    • Kang, Y.1    Ohtsu, A.2    Van Cutsem, E.3    Rha, S.Y.4    Sawaki, A.5    Park, S.6    Lim, H.7    Wu, J.8    Langer, B.9    Shah, M.A.10
  • 26
    • 66149133167 scopus 로고    scopus 로고
    • International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
    • Price TJ, Gebski V, van Hazel GA, Robinson BA, Broad A, Ganju V, Cunningham D, Wilson K, Tunney V, Tebbutt NC (2008) International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. J Clin Oncol 26:4029
    • (2008) J Clin Oncol , vol.26 , pp. 4029
    • Price, T.J.1    Gebski, V.2    Van Hazel, G.A.3    Robinson, B.A.4    Broad, A.5    Ganju, V.6    Cunningham, D.7    Wilson, K.8    Tunney, V.9    Tebbutt, N.C.10
  • 29
    • 0029983193 scopus 로고    scopus 로고
    • The importance of quality of primary studies in producing unbiased systematic reviews
    • DOI 10.1001/archinte.156.6.661
    • Khan KS, Daya S, Jadad A (1996) The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 156:661-666 (Pubitemid 26095017)
    • (1996) Archives of Internal Medicine , vol.156 , Issue.6 , pp. 661-666
    • Khan, K.S.1    Daya, S.2    Jadad, A.R.3
  • 31
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • DOI 10.1016/0197-2456(86)90046-2
    • DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188 (Pubitemid 17189972)
    • (1986) Controlled Clinical Trials , vol.7 , Issue.3 , pp. 177-188
    • DerSimonian, R.1    Laird, N.2
  • 32
    • 70349393610 scopus 로고    scopus 로고
    • Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials
    • Je Y, Schutz FA, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974
    • (2009) Lancet Oncol , vol.10 , pp. 967-974
    • Je, Y.1    Schutz, F.A.2    Choueiri, T.K.3
  • 33
    • 34250365240 scopus 로고    scopus 로고
    • Mechanisms of adverse effects of anti-VEGF therapy for cancer
    • DOI 10.1038/sj.bjc.6603813, PII 6603813
    • Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795 (Pubitemid 46912024)
    • (2007) British Journal of Cancer , vol.96 , Issue.12 , pp. 1788-1795
    • Kamba, T.1    McDonald, D.M.2
  • 34
    • 0142121282 scopus 로고    scopus 로고
    • Bevacizumab, bleeding, thrombosis, and warfarin
    • Kilickap S, Abali H, Celik I (2003) Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 21:3542-3543
    • (2003) J Clin Oncol , vol.21 , pp. 3542-3543
    • Kilickap, S.1    Abali, H.2    Celik, I.3
  • 35
    • 34249748593 scopus 로고    scopus 로고
    • A study of clinical and radiographic risk factors associated with early onset severe pulmonary hemorrhage in bevacizumab (Avastin) treated patients with advanced non-small cell lung cancer
    • SandlerAB JDH, Brahmer J et al (2006) A study of clinical and radiographic risk factors associated with early onset severe pulmonary hemorrhage in bevacizumab (Avastin) treated patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 24:7068
    • (2006) Proc Am Soc Clin Oncol , vol.24 , pp. 7068
    • Sandler, A.B.J.D.H.1    Brahmer, J.2
  • 36
    • 63049122188 scopus 로고    scopus 로고
    • Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall- cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab
    • Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH (2009) Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall- cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27:1405-1412
    • (2009) J Clin Oncol , vol.27 , pp. 1405-1412
    • Sandler, A.B.1    Schiller, J.H.2    Gray, R.3    Dimery, I.4    Brahmer, J.5    Samant, M.6    Wang, L.I.7    Johnson, D.H.8
  • 38
    • 58749110442 scopus 로고    scopus 로고
    • Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRITE observational cohort study (OCS)
    • Flynn PJ, Sugrue MM, Feng S, Purdie DM, Grothey A, Sargent DJ, Berlin JD, Kabbinavar FF, Dong W, Kozloff MF (2008) Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRITE observational cohort study (OCS). J Clin Oncol 26:4104
    • (2008) J Clin Oncol , vol.26 , pp. 4104
    • Flynn, P.J.1    Sugrue, M.M.2    Feng, S.3    Purdie, D.M.4    Grothey, A.5    Sargent, D.J.6    Berlin, J.D.7    Kabbinavar, F.F.8    Dong, W.9    Kozloff, M.F.10
  • 39
    • 78049382933 scopus 로고    scopus 로고
    • Increased risk of serious hemorrhage with bevacizumab in cancer patients: A meta-analysis
    • Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79:27-38
    • (2010) Oncology , vol.79 , pp. 27-38
    • Hapani, S.1    Sher, A.2    Chu, D.3    Wu, S.4
  • 40
    • 0032501730 scopus 로고    scopus 로고
    • Summing up evidence: One answer is not always enough
    • DOI 10.1016/S0140-6736(97)08468-7
    • Lau J, Ioannidis JPA, Schmid CH (1997) summing up the evidence: one answer is not always enough. Lancet 351:123-127 (Pubitemid 28026648)
    • (1998) Lancet , vol.351 , Issue.9096 , pp. 123-127
    • Lau, J.1    Ioannidis, J.P.A.2    Schmid, C.H.3
  • 41
    • 0028152471 scopus 로고
    • Why sources of heterogeneity in metaanalysis should be investigated
    • Thompson SG (1994) Why sources of heterogeneity in metaanalysis should be investigated. Br Med J 309:1351-1355
    • (1994) Br Med J , vol.309 , pp. 1351-1355
    • Thompson, S.G.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.